Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

NCT04522544 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Non-resectable
HCC

Interventions

DRUG: Tremelimumab
DRUG: Durvalumab
PROCEDURE: Y-90 SIRT
PROCEDURE: DEB-TACE

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators

AstraZeneca
Hannover Medical School